Seer Inc 2026年季度报告

(Mark one)[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 SEER, INC. (Exact name of Registrant as specified in its charter) 3800 Bridge Parkway, Suite 102Redwood City, California 94065650-453-0000 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerginggrowth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 ofthe Exchange Act. Large accelerated filer☐Accelerated filer☐Smaller reporting company☒Non-accelerated filer☒Emerging growth company☐If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of May 8, 2026, the registrant had 54,981,551 shares of Class A common stock, $0.00001 par value per share, outstanding. TABLE OF CONTENTS PART I.FINANCIAL INFORMATION1Item 1.Financial Statements (Unaudited)1Condensed Consolidated Balance Sheets1Condensed Consolidated Statements of Operations and Comprehensive Loss2Condensed Consolidated Statements of Stockholders’ Equity3Condensed Consolidated Statements of Cash Flows5Notes to Unaudited Condensed Consolidated Financial Statements6Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3.Quantitative and Qualitative Disclosures About Market Risk25Item 4.Controls and Procedures25PART II.OTHER INFORMATION27Item 1.Legal Proceedings27Item 1A.Risk Factors27Item 2.Unregistered Sales of Equity Securities83Item 3.Defaults Upon Senior Securities83Item 4.Mine Safety Disclosure83Item 5.Other Information83Item 6.Exhibits84Signatures SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (Quarterly Report) contains forward-looking statements. All statements other than statements ofhistorical facts contained in this Quarterly Report, including statements regarding our future results of operations and financialposition, business strategy, commercial activities and costs, research and development costs, timing and likelihood of success, as wellas plans and objectives of management for future operations, are forward-looking statements. These statements involve known andunknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results,performance or achievements to be materially different from any future results, performance or achievements expressed or implied bythe forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,”“anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential,” or “continue” or the negative of theseterms or other similar expressions. Forward-looking statements contained in this Quarterly Report include, but are not limited to,statements about: •estimates of our addressable market, market growth, key performance indicators, capital requirements and our needs foradditional financing;•our expectations regarding our financial performance, including among others, revenue, cost of revenue, gross profit,operating expenses, loss from operations and net losses;•our ability to successfully execute our commercial strategy and attract customers, including our plans for internationalexpansion;•the implementation of our business model, strategic plans and pricing for the Proteograph™ Product Suite;•our expectations regarding the rate and degree of market acceptance of the Proteograph Product Suite;•the impact of the Proteograph Product Suite on the field of proteomics and the size and growth of the addressable proteomicsmarket;•competitive companies and technologies and our industry;•our ability to manage and grow our business;•our ability to develop and commercialize new products;•our ability to establish and maintain intell